Free Trial
→ Market Panic: Trump Just Dropped a Bomb on Your Stocks (From American Alternative) (Ad)tc pixel

Zhengye Biotechnology (NASDAQ:ZYBT) Trading 17.1% Higher - Time to Buy?

Written by MarketBeat
September 17, 2025
Zhengye Biotechnology logo with Medical background

Key Points

  • Zhengye Biotechnology (NASDAQ:ZYBT) shares surged by 17.1% on Monday, reaching a trading high of $10.91 after closing at $9.32.
  • Analysts from Wall Street Zen have upgraded the company's rating to a "hold" as of August 2nd.
  • Several institutional investors, including Jane Street Group LLC, have made significant new investments in Zhengye Biotechnology during the second quarter.
  • Five stocks we like better than Zhengye Biotechnology.

Zhengye Biotechnology Holding Limited (NASDAQ:ZYBT - Get Free Report) shares rose 17.1% on Monday . The company traded as high as $10.91 and last traded at $10.91. Approximately 169,438 shares were traded during mid-day trading, a decline of 45% from the average daily volume of 310,313 shares. The stock had previously closed at $9.32.

Wall Street Analysts Forecast Growth

Separately, Wall Street Zen upgraded Zhengye Biotechnology to a "hold" rating in a research note on Saturday, August 2nd.

Get Our Latest Analysis on Zhengye Biotechnology

Zhengye Biotechnology Trading Down 0.8%

The company has a current ratio of 1.31, a quick ratio of 0.88 and a debt-to-equity ratio of 0.01. The firm has a 50-day simple moving average of $7.36 and a two-hundred day simple moving average of $7.18.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of the stock. Jane Street Group LLC bought a new position in shares of Zhengye Biotechnology in the second quarter worth $1,158,000. Invesco Ltd. bought a new position in shares of Zhengye Biotechnology in the second quarter worth $220,000. Finally, Geode Capital Management LLC bought a new position in shares of Zhengye Biotechnology in the second quarter worth $174,000.

About Zhengye Biotechnology

(Get Free Report)

Zhengye Biotechnology Holding Limited is a veterinary vaccine manufacturer which encompasses research, development, manufacturing and sales of veterinary vaccines, with a focus on livestock vaccine principally in China. Zhengye Biotechnology Holding Limited is based in Jilin, China.

See Also

Should You Invest $1,000 in Zhengye Biotechnology Right Now?

Before you consider Zhengye Biotechnology, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Zhengye Biotechnology wasn't on the list.

While Zhengye Biotechnology currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

The Best Nuclear Energy Stocks to Buy Cover
The Best Nuclear Energy Stocks to Buy

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report
Like this article? Share it with a colleague.